An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma
Categories (click each to see list of all clinical trials associated with that category): Lymphoma/CLL (ONC)
Current Status: Open
Phase: I (Cancer Control)
Principal Investigator: D'Angelo, Christopher
Contact Information:
Maribeth Hohenstein, RN
402-559-9053
mahohens@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT03328078?term=NCT03328078&rank=1
Summary
Part A (Dose Escalation Phase): To determine the safety and tolerability, DLTs, MTD, and RP2D of oral CA-4948 as monotherapy and in combination with ibrutinib
Part B Safety of CA-4948 in combination with ibrutinib in patients with PCNSL